Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
NeuroQuantology ; 20(15):6282-6291, 2022.
Article in English | EMBASE | ID: covidwho-2265814

ABSTRACT

During pandemic many people died as a result of the covid-19 sickness, which appeared in 2019 and spread over the world. The objective of research work is to wards the occurrence of COVID to improve classification accuracy and threshold curve predictions on real-life dataset for Receiver Operator Characteristics (ROC) value. This paper goals the real-life COVID patients from the five countries to test the experiment. The proposed methodology involves of two steps;used Weka for calculating the accuracy by applying Decision Table machine learning classifier and compare the results of all the five countries, secondly, the improvement in ROC value in terms of initial care predictions by area under ROC analysis. For our COVID dataset has 209 instances and 16 attributes, Weka has performed on the number of training instances are 184, number of Rules applied is 20, search direction has been applied in forward direction, total number of subsets evaluated is 96, merit of best subset found is 82.609 and time taken to build model is 0. 06 seconds. One advantage of our suggested mode list hat it keeps the original data intact, ensuring experiment quality. A further advantage is that the model can be used with additional data sets to produce the highest accuracy and ROC analysis out comes.Copyright © 2022, Anka Publishers. All rights reserved.

2.
International Journal of Pharmaceutical and Clinical Research ; 15(1):1-11, 2023.
Article in English | EMBASE | ID: covidwho-2218805

ABSTRACT

Background: Health care workers (HCW's) belong to high-risk group and at the same time being the role model to the general population. Current study was undertaken to assess the general level of trust, acceptance and fear on different COVID-19 vaccines among them. Material(s) and Method(s): An online questionnaire were distributed to all the HCW's through WhatsApp link between 1 March 2022 and 30 April 2022 to evaluate the perception and practices on different COVID 19 vaccines and precautionary dose using a snowball sampling method using self-designed structured questionnaire. Result(s): A total of 434 HCWs participated, with doctors (38.5%) and nursing staff (44.30%) nursing students (9.50%), medical students (6%) and others (1.70%). 96% were vaccinated for both first and second dose with only 32.3% for precautionary dose. The main reason for not receiving second dose is that 30 were recently positive for COVID infection and 17 respondents were not convinced with study results. Only 2% took different vaccine for second dose due to non-availability of first vaccine, doubt regarding the efficacy of the vaccine, belief in taking two different vaccines for stronger immunity. Participants took different vaccine for precautionary dose due to non-availability of the vaccine (15.4%), belief in taking two different vaccines provides stronger immunity (76.9%) and shift of residence (7.7%). Conclusion(s): Majority of the HCW's in our study have a modest acceptance towards second dose and precautionary dose. Institutions and other health care set up should scale up educational efforts to disseminate reliable information about different COVID vaccine and provide recommendations about receiving a vaccine booster to promote herd immunity. Copyright © 2023, Dr Yashwant Research Labs Pvt Ltd. All rights reserved.

3.
Medicine (Baltimore) ; 100(51): e28244, 2021 Dec 23.
Article in English | MEDLINE | ID: covidwho-1593779

ABSTRACT

RATIONALE: Bordetella bronchiseptica is a common cause of upper respiratory tract infections in domesticated dogs and cats and a rare zoonotic pathogen in immunocompromised humans. With increasing numbers of people acquiring pets and spending time with them in confined spaces due to COVID-19 lockdowns, it is important to be aware of adverse health consequences brought about by this interaction. We present a case of B bronchiseptica pneumonia in a patient with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and review key characteristics of an additional 30 cases of B bronchiseptica infections in 29 patients with HIV/AIDS that were identified by literature review. PATIENT CONCERNS: A 61-year-old male with HIV/AIDS who was not on antiretroviral therapy and had advanced immunosuppression with a CD4+ T-lymphocyte count of 3 cells/µL sought medical attention for multiple somatic issues including subjective fevers, shortness of breath, and intermittent chest pain. DIAGNOSIS: Computed tomography of the chest identified bilateral nodular opacities in the lower lobes with scattered areas of ground glass opacities. B bronchiseptica was identified in sputum culture by mass spectrometry followed by supplementary biochemical testing. INTERVENTIONS: Empiric broad-spectrum antibiotics were initiated and changed to levofloxacin after susceptibility testing was completed. OUTCOMES: The patient was discharged after symptomatic improvement with levofloxacin. LESSONS: Pneumonia with interstitial infiltrates in the setting of advanced CD4 lymphocyte depletion is the most common clinical syndrome caused by B bronchiseptica in patients with HIV/AIDS, and may be accompanied by sepsis. Advanced immune suppression, as well as chronic medical conditions, for example, alcoholism, diabetes, and renal failure that compromise host defenses are also commonly found in cases of B bronchiseptica infection in patients who do not have HIV infection. Reported animal contact among patients was not universal. Isolates were susceptible to aminoglycosides, carbapenems, fluoroquinolones, but typically resistant to most cephalosporins.


Subject(s)
Acquired Immunodeficiency Syndrome , Bordetella Infections , Bordetella bronchiseptica , HIV Infections , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/microbiology , Anti-Bacterial Agents/therapeutic use , Bordetella Infections/complications , Bordetella Infections/diagnosis , Bordetella Infections/drug therapy , HIV Infections/complications , HIV Infections/microbiology , Humans , Levofloxacin/therapeutic use , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL